מדינה: אירלנד
שפה: אנגלית
מקור: HPRA (Health Products Regulatory Authority)
TENOXICAM
Roche Products Limited
TENOXICAM
20 Milligram
Unknown
Withdrawn
2008-03-04
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mobilflex Vials 20 mg Powder and Solvent for Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 Vial contains 20 mg tenoxicam. 1 Ampoule contains 2 ml water for injections. The reconstituted solution gives a tenoxicam concentration of 10 mg/ml. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection Powder: A green-yellow coloured powder. Solvent: Clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mobiflex is indicated for the relief of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for the short term management of acute musculoskeletal disorders including strains, sprains and other soft- tissue injuries. IV, IM tenoxicam is available for these indications in those patients considered unable to take oral tenoxicam. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ADULTS_ Mobiflex Vials should be given IV or IM. A single daily dose of 20mg for one to two days initially to be continued with the oral form, with administration at the same time each day. For patients needing long-term treatment a reduction to a daily oral dose of 10mg may be tried for maintenance. The lyophilisate should be dissolved in 2ml of the solvent provided (2ml sterile water for injections). This reconstituted solution should be used immediately. Higher doses should be avoided as they do not usually achieve significantly greater therapeutic effect but may be associated with a higher risk of adverse events. In acute musculoskeletal disorders treatment should not normally be required for more than 7 days, but in severe cases it may be continued up to a maximum of 14 days. _ELDERLY_ As with other non-steroidal anti- קרא את המסמך השלם